FILE CO

SAL IWANCH I K JUN-30-04 WED 11:24 AM

FAX NO. 3523725800

FACSIMILE COVER SHEET

AND STRAILE COPL Saliwanchik, Lloyd & Saliwanchik

A Professional Association 2421 N.W. 41st Street Suite A-1 Gainesville, FL 32606

Telephone (352) 375-8100 Facsimile (352) 372-5800

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

TO:

Office of Initial Patent Examination's Filing Receipt Corrections

COMPANY: United States Patent Office

FAX NO.:

703-746-9195

FROM:

Frank C. Eisenschenk, Ph.D.

DATE:

June 30, 2004

NUMBER OF PAGES (INCLUDING COVER SHEET): 13

SUBJECT/MESSAGE:

Re:

U.S. Patent Application Docket No. TPI-2900C3XC2

PHARMACEUTICAL PROPYLENE GLYCOL SOLVATE COMPOSITIONS

(Tawa, Almarsson, Remenar)

Scrial No. 10/747,742; filed December 29, 2003

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

H:\doc\fax\OFR.correct.doc/DNH/sl

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on Jove 30, 2004

Frank C. Eisenschenk, Ph.D., Patent Attorney

REQUEST FOR CORRECTION OF FILING RECEIPT Examining Group 1614

Patent Application

Docket No. TPI-2900C3XC2

Serial No. 10/747,742

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

1614

Applicants

Mark Tawa, Örn Almarsson, Julius F. Remenar

Serial No.

10/747,742

Filed

December 29, 2003

Conf. No.

2066

For

Pharmaccutical Propylene Glycol Solvate Compositions

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

Applicants respectfully request the correction of errors in the Filing Receipt for the aboveidentified patent application. Please send a corrected Filing Receipt with the following changes:

The Filing Receipt lists the Domestic Priority data as claimed by applicant as:

This appln claims benefit of 60/437,516	12/30/2002
and claims benefit of 60/441,335	01/21/2003
and claims benefit of 60/456,027	03/18/2003
and claims benefit of 60/456,608	03/21/2003
and claims benefit of 60/459,501	04/01/2003
and claims benefit of 60/486,713	07/11/2003
and is a CIP of 10/601,092	
which claims benefit of 60/390,881	06/21/2002
and claims benefit of 60/426,275	11/14/2002
and claims benefit of 60/427,086	11/15/2002
and claims benefit of 60/429,515	11/26/2002
and claims benefit of 60/437,516	12/30/2002
and claims benefit of 60/456,027	03/18/2003

JNTPA2900C3XC2\PTO\Req.com.FR.doc/DNT/sl

Docket No. TPI-2900C3XC2
Serial No. 10/747,742

and is a CIP of PCT/US03/19574	06/20/2003
which claims benefit of 60/390,881	06/21/2002
and claims benefit of 60/426,275	11/14/2002
and claims benefit of 60/427,086	11/15/2002
and claims benefit of 60/429,515	11/26/2002
and claims benefit of 60/437,516	12/30/2002
and claims benefit of 60/456,027	03/18/2003

2

The correct Domestic Priority data as claimed by applicant is:

This appln claims benefit of 60/486,713	07/11/2003
and claims benefit of 60/459,501	04/01/2003
and claims benefit of 60/456,608	03/21/2003
and claims benefit of 60/456,027	03/18/2003
and claims benefit of 60/441,335	01/21/2003
and claims benefit of 60/437,516	12/30/2002
and is a CIP of 10/601,092	06/20/2003
which claims benefit of 60/390,881	06/21/2002
and claims benefit of 60/426,275	11/14/2002
and claims benefit of 60/427,086	11/15/2002
and claims benefit of 60/429,515	11/26/2002
and claims benefit of 60/437,516	12/30/2002
and claims benefit of 60/456,027	03/18/2003
and is a CIP of PCT/US03/19574	06/20/2003
which claims benefit of 60/390,881	06/21/2002
and claims benefit of 60/426,275	11/14/2002
and claims benefit of 60/427,086	11/15/2002
and claims benefit of 60/429,515	11/26/2002
and claims benefit of 60/437,516	12/30/2002
and claims benefit of 60/456,027	03/18/2003
and is a CIP of PCT/US03/41273	12/24/2003
which is a CIP of 10/601,092	06/20/2003
Said 10/601,092	
claims benefit of 60/390,881	06/21/2002
and claims benefit of 60/426,275	11/14/2002
and claims benefit of 60/427,086	11/15/2002
and claims benefit of 60/429,515	11/26/2002
and claims benefit of 60/437,516	12/30/2002
and claims benefit of 60/456,027	03/18/2003
Said PCT/US03/41273	
is also a CIP of PCT/US03/19574	06/20/2003
and claims benefit of 60/390,881	06/21/2002

JATPI\2900C3XC2\PTO\Req.com FR.doc/DNB/st

Docket No.	TPI-2	900C3XC2
Seri	al No.	10/747,742

and claims benefit of 60/426,275	11/14/2002
and claims benefit of 60/427,086	11/15/2002
and claims benefit of 60/429,515	11/26/2002
and claims benefit of 60/437,516	12/30/2002
and claims benefit of 60/456,027	03/18/2003
Said PCT/US03/41273	
is a CIP of 10/660,202	09/11/2003
which is a CIP of PCT/US03/27772	09/04/2003
which is a CIP of 10/378,956	03/03/2003
which claims benefit of 60/360,768	03/01/2002
Said PCT/US03/27772	
claims benefit of 60/451,213	02/28/2003
and claims benefit of 60/463,962	04/18/2003
and claims benefit of 60/487,064	07/11/2003
Said 10/660,202	
is also a CIP of 10/637,829	08/08/2003
which is a division of 10/295,995	11/18/2002
which is a continuation of 10/232,589	09/03/2002
which claims beenfit of 60/406,974	08/30/2002
and claims benefit of 60/380,288	05/15/2002
and claims benefit of 60/356,764	02/15/2002
Said 10/660,202	
is also a CIP of 10/449,307	05/30/2003
which claims benefit of 60/463,962	04/18/2003
and claims benefit of 60/444,315	01/31/2003
and claims benefit of 60/439,282	01/10/2003
and claims benefit of 60/384,152	05/31/2002
Said 10/660,202	06/00/0000
is also a CIP of 10/601,092	06/20/2003
Said 10/660,202	02/28/2002
claims the benefit of 60/451,213	02/28/2003
and claims benefit of 60/463,962	04/18/2003
and claims benefit of 60/487,064	07/11/2003
Said PCT/US03/41273	10/20/2002
claims benefit of 60/437,516	12/30/2002 01/21/2003
and claims benefit of 60/441,335	03/21/2003
and claims benefit of 60/456,608	04/01/2003
and claims benefit of 60/459,501	04/01/2003
and claims benefit of 60/486,713	07/11/2003.

3

4

Docket No. TPI-2900C3XC2 Serial No. 10/747,742

Please send a corrected Filing Receipt showing all the domestic priority data as claimed by Applicants. A copy of the Filing Receipt is attached, along with a copy of Applicants' Preliminary Amendment dated April 21, 2004 showing the correct priority information. Because of the length of the correction, Applicants have not noted the changes thereon but rely on pages 2-4 of their Preliminary Amendment and the previously submitted Declaration (37 C.F.R. § 1.63) and Power of Attorney form executed by the Applicants. It appears that the priority claimed on pages 3 and 4 may have been inadvertently omitted by the Patent Office when preparing the Updated Filing Receipt.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.:

352-375-8100

Fax No.:

352-372-5800

RANK CEnsuschen

Address:

2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606-6669

FCE/s1

Attachments: copy of Filing Receipt; copy of Preliminary Amendment



Page 1 of 3




United States Patent and Trademark Office

UNITED STATICS DEPARTMENT OF COMMERCE United States Patient and Tendennick Office Address COMMESSIONER FUR FATENTS (1) 024 1450 Alexandra, Vaguin 23113-1450 www.babbapa.

I	APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY, DOCKET NO	ORAWINGS	TOT CLMS	IND CLMS	
1	10/747 742	12/29/2003	1614	493	TPI-2900C3XC2	15	6	4	

CONFIRMATION NO. 2066

SALIWANCHIK LLOYD & SALIWANCHII A PROFESSIONAL ASSOCIATION 2421 N.W. 41ST STREET SUITE A-1 **GAINESVILLE, FL 32606-6669**



Date Mailed: 06/18/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Mark Tawa, Brighton, MA; Om Almarsson, Shrewsbury, MA; Julius Remenar, Framingham, MA;

Assignment For Published Patent Application

TransForm Pharmaceuticals, Inc., Lexington, MA;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/437,516 12/30/2002 and claims benefit of 60/441,335 01/21/2003 and claims benefit of 60/456,027 03/18/2003 and claims benefit of 60/456,608 03/21/2003 and claims benefit of 60/459,501 04/01/2003 and claims benefit of 60/486,713 07/11/2003 and is a CIP of 10/601,092 which claims benefit of 60/390,881 06/21/2002 and claims benefit of 60/426,275 11/14/2002 and claims benefit of 60/427,086 11/15/2002 and claims benefit of 60/429,515 11/26/2002 and claims benefit of 60/437,516 12/30/2002 and claims benefit of 60/456,027 03/18/2003 and is a CIP of PCT/US03/19574 06/20/2003 which claims benefit of 60/390,881 06/21/2002 and claims benefit of 60/426,275 11/14/2002

12/30/2002
12/30/2002
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2002
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2003
12/30/2000
12/30/2000
12/30/2000
12/30/2000
12/30/2000
12/30/2000

Page 2 of 3

and claims benefit of 60/427,086 11/15/2002 and claims benefit of 60/429,515 11/26/2002 and claims benefit of 60/437,516 12/30/2002 and claims benefit of 60/456,027 03/18/2003

Foreign Applications

If Required, Foreign Filing License Granted: 04/09/2004

Projected Publication Date: 09/30/2004

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Pharmaceutical propylene glycol solvate compositions

Preliminary Class

514

ALAILABILE CORL

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (i)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING

LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

FAX NO. 3523725800